SciRent SciRent
  • Home
  • Who we are
  • Our Services
  • Team
  • Ongoing Trials
  • Contact
photo - SPIHF-203

SPIHF-203

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of special 4 Weeks Treatment

Aim

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Preserved Ejection Fraction
Study Phase: Phase 2
Study Number: SPIHF-203
EudraCT Number: 2015-005615-32
Sponsor:
Stealth BioTherapeutics Inc.
275 Grove Street, Suite 3-107 Newton, MA 02466 Unites States of America

Patient collective
Patients with stable heart failure with preserved ejection fraction (HFpEF)

Study procedure
This is a randomized, double-blinded, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF). After completing the screening period, 46 subjects will be randomized, in a 1:1 ratio, to receive either 40 mg elamipretide once daily or placebo for 28 consecutive days on top of usual care .

 

Patients enrolled in study
47

Study centers
9 centers in two countries (Germany and Serbia)

Copyrights 2019 SciRent